AR and neoplasm: The mechanism of action for enzalutamide is threefold: (1) it is a potent, competitive binder of androgens at the level of the AR; (2) it prevents the translocation of the AR from the cytoplasm to the nucleus; and (3) in the nucleus, it inhibits AR binding to chromosomal DNA, which prevents the further transcription of tumor genes.